This lower survival rate for subtype 2 tumours suggests that the combination of CIMP and BRAF mutation confers a poor prognosis in stable tumours, whereas the same combination in tumours with MSI (i.e., subtype 1) evolves in a completely different way. This evidence concerns the gene BRAF and neoplasm.